Jiangsu Hengrui Medicine Earnings Seen Weighed by Costs, Lower Sales -- Market Talk

Dow Jones

2025/10/30

0600 GMT - HSBC cuts earnings forecasts for Jiangsu Hengrui Medicine for 2025-2027 by 2%-5%, weighed by lower sales and higher costs. Product sales for 2025-2027 are seen weaker due to intensive domestic competition, while selling and administrative expenses are seen rising to support new drug launches. However, HSBC keeps revenue estimates for the same period unchanged, with higher business development revenue from strong product pipeline offsetting weaker product sales. HSBC lowers the stock's target price to CNY77.00 from CNY79.00 but maintains a buy rating as it remains optimistic on Hengrui's long-term growth outlook. The A-shares were last at CNY63.63. (jason.chau@wsj.com)

(END) Dow Jones Newswires

October 30, 2025 02:00 ET (06:00 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579096162"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579096162\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579096162?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579096162","market":"nz","top_or_hot":-1,"title":"Jiangsu Hengrui Medicine Earnings Seen Weighed by Costs, Lower Sales -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0600 GMT - <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> cuts earnings forecasts for <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Medicine for 2025-2027 by 2%-5%, weighed by lower sales and higher costs. Product sales for 2025-2027 are seen weaker due to intensive domestic competition, while selling and administrative expenses are seen rising to support new drug launches. However, HSBC keeps revenue estimates for the same period unchanged, with higher business development revenue from strong product pipeline offsetting weaker product sales. HSBC lowers the stock's target price to CNY77.00 from CNY79.00 but maintains a buy rating as it remains optimistic on Hengrui's long-term growth outlook. The A-shares were last at CNY63.63. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 02:00 ET (06:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Hengrui Medicine Earnings Seen Weighed by Costs, Lower Sales -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Hengrui Medicine Earnings Seen Weighed by Costs, Lower Sales -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-30 14:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0600 GMT - <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> cuts earnings forecasts for <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Medicine for 2025-2027 by 2%-5%, weighed by lower sales and higher costs. Product sales for 2025-2027 are seen weaker due to intensive domestic competition, while selling and administrative expenses are seen rising to support new drug launches. However, HSBC keeps revenue estimates for the same period unchanged, with higher business development revenue from strong product pipeline offsetting weaker product sales. HSBC lowers the stock's target price to CNY77.00 from CNY79.00 but maintains a buy rating as it remains optimistic on Hengrui's long-term growth outlook. The A-shares were last at CNY63.63. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 02:00 ET (06:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0634319403.HKD","symbol_name":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579096162","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579096162","pubTimestamp":1761804000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0600 GMT - HSBC cuts earnings forecasts for Jiangsu Hengrui Medicine for 2025-2027 by 2%-5%, weighed by lower sales and higher costs. Product sales for 2025-2027 are seen weaker due to intensive domestic competition, while selling and administrative expenses are seen rising to support new drug launches. However, HSBC keeps revenue estimates for the same period unchanged, with higher business development revenue from strong product pipeline offsetting weaker product sales. HSBC lowers the stock's target price to CNY77.00 from CNY79.00 but maintains a buy rating as it remains optimistic on Hengrui's long-term growth outlook. The A-shares were last at CNY63.63. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","BK1601":"香港本地股","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK4585":"ETF&股票定投概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","HSBC":"汇丰","HSHD.SI":"HSBC HK SDR 5to1","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","03143":"华夏香港银行股","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0239":"医药制造","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","00005":"汇丰控股","BK1231":"综合性银行","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK4521":"英国银行股","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1572":"香港银行股","BK0183":"MSCI概念","BK4588":"碎股","BK0012":"证金概念","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","HSBA.UK":"汇丰控股有限公司","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","BK0028":"国家队","BK4207":"综合性银行","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","BK1610":"ETF&股票定投概念","LU1997245177.USD":"安联神洲A股基金","BK0060":"抗癌","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC"},"translate_title":"江苏恒瑞医药盈利受成本拖累，销售额下降——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"00005":0.9,"HSHD.SI":0.6,"03143":0.6,"HSBC":0.9,"HSBA.UK":0.6},"content_text":"0600 GMT - HSBC cuts earnings forecasts for Jiangsu Hengrui Medicine for 2025-2027 by 2%-5%, weighed by lower sales and higher costs. Product sales for 2025-2027 are seen weaker due to intensive domestic competition, while selling and administrative expenses are seen rising to support new drug launches. However, HSBC keeps revenue estimates for the same period unchanged, with higher business development revenue from strong product pipeline offsetting weaker product sales. HSBC lowers the stock's target price to CNY77.00 from CNY79.00 but maintains a buy rating as it remains optimistic on Hengrui's long-term growth outlook. The A-shares were last at CNY63.63. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 02:00 ET (06:00 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}